ESSA’s proprietary 'aniten' compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

The North American company is currently progressing IND-enabling studies and expects to file an IND with the US Food and Drug Administration for EPI-7386 in the first calendar quarter of 2020.